<bill session="118" type="s" number="775" updated="2025-04-21T12:24:17Z">
  <state datetime="2023-03-14">REFERRED</state>
  <status>
    <introduced datetime="2023-03-14"/>
  </status>
  <introduced datetime="2023-03-14"/>
  <titles>
    <title type="display">Increasing Transparency in Generic Drug Applications Act</title>
    <title type="short" as="introduced">Increasing Transparency in Generic Drug Applications Act</title>
    <title type="official" as="introduced">A bill to provide for increased transparency in generic drug applications.</title>
  </titles>
  <sponsor bioguide_id="H001076"/>
  <cosponsors>
    <cosponsor bioguide_id="B001310" joined="2023-03-28"/>
    <cosponsor bioguide_id="H000273" joined="2023-04-25"/>
    <cosponsor bioguide_id="P000603" joined="2023-03-14"/>
  </cosponsors>
  <actions>
    <action datetime="2023-03-14">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2023-03-14" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referred To"/>
  </committees>
  <relatedbills>
    <bill session="118" type="h" number="3561" relation="unknown"/>
    <bill session="118" type="s" number="1114" relation="unknown"/>
    <bill session="118" type="h" number="3839" relation="unknown"/>
    <bill session="118" type="h" number="5378" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2023-10-02T19:37:32Z" status="Introduced in Senate">Increasing Transparency in Generic Drug Applications Act

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.</summary>
</bill>
